Back to results
US 2025/0066438 A1Published application
Methods and compositions for preventing or treating cancer
OwnerEriona HYSOLLI, Evan APPLETON +1inventors
InventorsEriona HYSOLLI, Evan APPLETON, Ben E. LAMM
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating or preventing cancer in a subject in need thereof, the methods comprise administering to the subject in need thereof (a) one or more nucleic acids encoding an elephant p53 protein, an elephant LIF protein, and/or combinations thereof, or (b) one or more elephant p53 proteins, elephant LIF proteins, and/or combinations thereof. Also provided are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and (a) one or more nucleic acids encoding an elephant p53 protein, an elephant LIF protein, and/or combinations thereof, or (b) one or more elephant p53 proteins, elephant LIF proteins, and/or combinations thereof.
Claims39
A method of treating or preventing cancer in a subject in need thereof, the method comprising administering to the subject in need thereof:
- (a) one or more nucleic acids encoding an elephant p53 protein, wherein the one or more nucleic acids encoding the elephant p53 protein comprise a nucleotide sequence having at least 80% identity with a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, and combinations thereof;
- or
- (b) one or more elephant p53 proteins, wherein the one or more elephant p53 proteins comprise an amino acid sequence with at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NOs:75-133, and combinations thereof.
(canceled)
(canceled)
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and
- (a) one or more nucleic acids encoding an elephant p53 protein, wherein the one or more nucleic acids encoding the elephant p53 protein comprise a nucleotide sequence having at least 80% identity with a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, and combinations thereof;
- or
- (b) one or more elephant p53 proteins, wherein the one or more elephant p53 proteins comprise an amino acid sequence with at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NOs:75-133, and combinations thereof.
(canceled)
(canceled)
A kit for treating or preventing cancer in a subject in need thereof, the kit comprising:
- (a) one or more nucleic acids encoding an elephant p53 protein, wherein the one or more nucleic acids encoding the elephant p53 protein comprise a nucleotide sequence having at least 80% identity with a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, and combinations thereof;
- or
- (b) one or more elephant p53 proteins, wherein the one or more elephant p53 proteins comprise an amino acid sequence with at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NOs:75-133, and combinations thereof;
- and
- (c) instructions for use.
2 more elements
22-23. (canceled)
26-27. (canceled)
29-32. (canceled)
A method of treating or preventing cancer in a subject in need thereof, the method comprising administering to the subject in need thereof:
- (a) one or more nucleic acids encoding an elephant leukemia inhibitory factor (LIF) protein, wherein the one or more nucleic acids encoding the elephant LIF protein comprise a nucleotide sequence having at least 80% identity with a nucleotide sequence selected from the group consisting of SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, and combinations thereof;
- or
- (b) one or more elephant LIF proteins, wherein the one or more elephant LIF proteins comprise an amino acid sequence with at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NOs:134-140, and combinations thereof.
(canceled)
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and
- (a) one or more nucleic acids encoding an elephant leukemia inhibitory factor (LIF) protein, wherein the one or more nucleic acids encoding the elephant LIF protein comprise a nucleotide sequence having at least 80% identity with a nucleotide sequence selected from the group consisting of SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, and combinations thereof;
- or
- (b) one or more elephant LIF proteins, wherein the one or more elephant LIF proteins comprise an amino acid sequence with at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NOs:134-140, and combinations thereof.
42-44. (canceled)
A kit for treating or preventing cancer in a subject in need thereof, the kit comprising:
- (a) one or more nucleic acids encoding an elephant leukemia inhibitory factor (LIF) protein, wherein the one or more nucleic acids encoding the elephant LIF protein comprise a nucleotide sequence having at least 80% identity with a nucleotide sequence selected from the group consisting of SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, and combinations thereof;
- or
- (b) one or more elephant LIF proteins, wherein the one or more elephant LIF proteins comprise an amino acid sequence with at least 85% identity to an amino acid sequence selected from the group consisting of SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NOs:134-140, and combinations thereof;
- and
- (c) instructions for use.
2 more elements
46-52. (canceled)
Dependencies are inferred from the claim text.